Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
186
Views
1
CrossRef citations to date
0
Altmetric
Articles

TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study

Jie Mana Hematology and Oncology, Children’s Hospital of Fudan University, Shanghai, PR ChinaORCID Iconhttps://orcid.org/0000-0002-8416-5755View further author information
ORCID Icon,
Hongsheng Wanga Hematology and Oncology, Children’s Hospital of Fudan University, Shanghai, PR ChinaView further author information
,
Xiaowen Qiana Hematology and Oncology, Children’s Hospital of Fudan University, Shanghai, PR ChinaView further author information
,
Lian Chenb Pathology, Children's Hospital of Fudan University, Shanghai, PR ChinaView further author information
,
Yangyang Mab Pathology, Children's Hospital of Fudan University, Shanghai, PR ChinaView further author information
,
Maoxiang Qianc Institute of Pediatrics, Children’s Hospital of Fudan University, Shanghai, PR China;d The Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR ChinaView further author information
&
Xiaowen Zhaia Hematology and Oncology, Children’s Hospital of Fudan University, Shanghai, PR ChinaCorrespondence[email protected]
View further author information
 show all
Pages 2453-2460 | Received 28 Nov 2021, Accepted 06 May 2022, Published online: 26 May 2022

References

  • Levine AM. Challenges in the management of Burkitt’s lymphoma. Clin Lymphoma. 2002;3(1):S19–S25.
  • Jabbour E, Kantarjian H. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet. 2016;387(10036):2360–2361.
  • Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood. 2004;105(3):948–958.
  • Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90. Blood. 1999;94(10):3294–3306.
  • Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage-a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol. 1995;13(2):359–372.
  • Lopez CAO, Kleinheinz KAO, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat. Commun. 2019;10:1459.
  • Kwon K, Hutter C, Sun Q, et al. Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity. 2008;28(6):751–762.
  • Lazorchak AS, Wojciechowski J, Dai M, et al. E2A promotes the survival of precursor and mature B lymphocytes. J Immunol. 2006;177(4):2495–2504.
  • Patel D, Chinaranagari S, Chaudhary J. Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells. Am J Cancer Res. 2015;5(11):3407–3421.
  • Spender LC, Inman GJ. Developments in Burkitt’s lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res. 2014;6:27–38.
  • Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22(2):167–179.
  • Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–120.
  • Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127(20):2361–2364.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • McCarty KS, Jr., Miller LS, Cox EB, et al. Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716–721.
  • Specht E, Kaemmerer D, Sanger J, et al. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology. 2015;67(3):368–377.
  • Hirano S. Western blot analysis. Methods Mol Biol. 2012;926:87–97.
  • Luo L, Zhang H, Nian S, et al. Up-regulation of transcription factor 3 is correlated with poor prognosis in cervical carcinoma. Int J Gynecol Cancer. 2017;27(7):1422–1430.
  • Slyper M, Shahar A, Bar-Ziv A, et al. Control of breast cancer growth and initiation by the stem cell-associated transcription factor TCF3. Cancer Res. 2012;72(21):5613–5624.
  • Shen X, Yuan J, Zhang M, et al. The increased expression of TCF3 is correlated with poor prognosis in Chinese patients with nasopharyngeal carcinoma. Clin Otolaryngol. 2017;42(4):824–830.
  • Huang A, Zhao H, Quan Y, et al. E2A predicts prognosis of colorectal cancer patients and regulates cancer cell growth by targeting miR-320a. PLoS One. 2014;9(1):e85201.
  • Steininger A, Mobs M, Ullmann R, et al. Genomic loss of the putative tumor suppressor gene E2A in human lymphoma. J Exp Med. 2011;208(8):1585–1593.
  • Mukhtar F, Boffetta P, Risch HA, et al. Survival predictors of Burkitt’s lymphoma in children, adults and elderly in the United States during 2000–2013. Int J Cancer. 2017;140(7):1494–1502.
  • Pillon M, Mussolin L, Carraro E, et al. Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-Cell lymphoma treated with the AIEOP LNH-97 protocol. Br J Haematol. 2016;175(3):467–475.
  • Costa LJ, Xavier AC, Wahlquist AE, et al. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013;121(24):4861–4866.
  • Yamazaki T, Liu L, Erin G, et al. Burkitt lymphoma-related TCF3 mutations alter TCF3 alternative splicing by disrupting hnRNPH1 binding. RNA Biol. 2020;17(10):1383–1390.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.